v3.25.4
Non-Consolidated Affiliates (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2025
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Feb. 11, 2020
May 31, 2018
Schedule of Equity Method Investments [Line Items]                  
Equity method investments     $ 379,424   $ 289,968 $ 379,424      
Equity in income/(losses) of equity method investees         29,089 29,611 $ 28,882    
Distributions from equity method investees         105,149 23,641 43,882    
Distributions from equity method investees         13,396 13,396 18,823    
AstraZeneca | Avillion II                  
Schedule of Equity Method Investments [Line Items]                  
Milestone payment received $ 22,000   55,000            
Legacy Investors Partnerships                  
Schedule of Equity Method Investments [Line Items]                  
Equity method investments               $ 303,700  
Equity in income/(losses) of equity method investees         17,000 10,400 4,300    
Distributions from equity method investees         74,800 22,700 14,300    
Avillion Entities                  
Schedule of Equity Method Investments [Line Items]                  
Equity in income/(losses) of equity method investees         12,100 19,200 24,600    
Avillion I                  
Schedule of Equity Method Investments [Line Items]                  
Distributions from equity method investees         13,400 13,400 $ 13,600    
Avillion II                  
Schedule of Equity Method Investments [Line Items]                  
Distributions from equity method investees         3,000 1,000      
Other commitment                 $ 155,000
Proceeds exercise fee       $ 80,000          
Exercise fee, pro rata amount       $ 34,800          
Milestone payment received, pro rata amount $ 10,000 $ 27,400              
Unfunded Commitments Related To Avillion Entities                  
Schedule of Equity Method Investments [Line Items]                  
Other commitment     $ 10,300   $ 10,300 $ 10,300